Aoqi's pipeline covers APIs and excipients, finished and semi-finished formulations, technology licensing, and special products for human and animal health. Listed by category below; development status updated as projects advance.
| Product | Indication / Use | GMP |
|---|---|---|
| Tirzepatide | Diabetes, Obesity | FDANMPA |
| Semaglutide | Diabetes, Obesity | FDANMPA |
| Liraglutide | Diabetes, Obesity | FDANMPA |
| Linaclotide | Irritable Bowel Syndrome (IBS-C) / Chronic idiopathic constipation (CIC) | NMPA |
| NAD+ | Anti-aging | NMPAFDA |
| Penicillamine | Heavy metal poisoning / Wilson's disease / Active rheumatoid arthritis | EMANMPA |
| Dimercaptosuccinic Acid | Heavy metal poisoning / Wilson's disease | FDANMPA |
| Retatrutide | Diabetes, Obesity | FDANMPA |
| Tesamorelin | Women Health, ART | FDANMPA |
| Sermorelin | Women Health, ART | FDANMPA |
| BPC-157 | Musculoskeletal | FDANMPA |
| Selank Acetate | CNS | FDANMPA |
| SNAC | Excipient | EMANMPA |
| Product | Indication | Dosage Type | Type |
|---|---|---|---|
| Linaclotide Cap | IBS-C / CIC | Capsule, SemiFDF-particles | Generic |
| Semaglutide Tab | Diabetes, Obesity | Tablet, SemiFDF-particles | Generic |
| Inclisiran Injection | Hypercholesterolemia | Injection, API + preparation procedure, API + CMC CRO | Generic |
| Semaglutide Cap | Diabetes, Obesity | Capsule, SemiFDF-particles | Innovative |
| Tirzepatide Cap | Diabetes, Obesity | Capsule, SemiFDF-particles | Innovative |
| Product | Indication | Dosage | Strength |
|---|---|---|---|
| Tirzepatide Cap | Diabetes, Obesity | Capsule | — |
| Semaglutide Cap | Diabetes, Obesity | Capsule | 5mg, 10mg, 15mg |
High-barrier generics and complex formulations; development status updated as projects advance.
| Product | Originator | Indication | Status |
|---|---|---|---|
| Cyclosporin Eye Drops (ophthalmic emulsion) 0.05% Single Dose | Restasis (Allergan) | Dry eye syndrome | Approved IND in China, clinical trial developed in China |
| Azithromycin ophthalmic solution (2.5ml/bottle) | AzaSite (Inspire) | Bacterial conjunctivitis | Approved IND in China, clinical trial developed in China |
| Vitamin K1 Injection (1MG/0.5ML) | AQUAMEPHYTON (Teligent) | Vitamin K deficiency bleeding | File in China/US 2025 Q3/Q4 |
| SF6 Microbubble for Injection (59mg/61mg) | Sonovue® (Bracco) | Ultrasound contrast agent | File in China/US 2026 Q1/Q2 |
| Semaglutide Tablet (3mg/7mg/14mg) | Rybelsus (Novo Nordisk) | Diabetes, Obesity | BE studies in China and Malaysia both finished; approved in Pakistan |
| Linaclotide Capsules (290μg) | Linzess (AstraZeneca) | IBS-C, CIC, FC | Validation batch finished in China; file in China 2025 Q3 |
| C3F8 Microbubble for Injection (6.52mg/ml, 1.5ml) | DEFINITY (Lantheus) | Ultrasound contrast agent | Validation batch finished in China; filed in China 2025 Q1 |
| Aprocitentan Tablet (12.5mg/25mg) | JERAYGO (Idorsia) | Resistant hypertension | Pilot batch |
| Rimegepant Tablet (75mg ODT) | Nurtec (Pfizer) | Migraine | Pilot batch |
| Gepotidacin Tablet (750mg) | Blujepa (GSK) | Urinary tract infection | Pilot batch |
| Baloxavir Marboxil Tablet (20mg, 40mg) | Xofluza (Roche, Shionogi) | Anti-influenza virus | Pilot batch |
| Product | Indication | Status |
|---|---|---|
| Lidocaine micropellet | Anesthesia | Validation batch / clinical trials |
| Meloxicam nanocrystalline | Anesthesia | Validation batch / clinical trials |
Guanylate cyclase (GC-C) agonist
| Item | Detail |
|---|---|
| Originator | Ironwood Pharmaceuticals GmbH |
| Strength & dosage form | Capsules 72μg, 145μg, 290μg |
| Launch region | US (AbbVie), EMA (AbbVie), China (AstraZeneca), Japan (Astellas) |
| Indication | Irritable Bowel Syndrome (IBS-C) with constipation; chronic idiopathic constipation (CIC) |
| Patent | API expired by 2024; FDF expired by 2029 |
| Launch time | 2012 in US |
SNAC supplied by Aoqi
| Item | Detail |
|---|---|
| Originator | Novo Nordisk |
| API / FDF | API: Aoqi Biotech |
| Strength & dosage form | 1.5mg, 4mg, 9mg — Tablet |
| Launch region | US, EMA, Japan, China, Korea — more than 50 countries |
| Indication | Diabetes, Obesity |
| Patent | API expired by 2026; FDF by Novo expired by 2033 |
| Launch time | 2017 in US |
BE study: June 2024, 36 + 36 subjects, single oral dose, three-way crossover, 28-day washout.
SNAC-free technology package
| Item | Detail |
|---|---|
| Strength & dosage form | Capsules 3mg, 5mg, 10mg |
| Indication | Diabetes, Obesity |
| Patent | API expired by 2026; FDF by Novo expired by 2033 |
Clinical supply ramp-up: 5,000 capsules Dec 2024 → 20,000 Feb 2025 → 1,000,000 March 2025.
Development status and filing plans shown here are taken from Aoqi product materials for partnering discussion only. Supply, registration and documentation are governed by the executed technical and quality agreements. Chinese names are common translations; INN governs regulatory filings.
